Metabolic changes associated with adaptive resistance to daptomycin in Streptococcus mitis-oralis.
Adaptation, Physiological
Amino Acids
/ biosynthesis
Bacterial Proteins
/ genetics
Daptomycin
/ pharmacology
Drug Resistance, Bacterial
Genetic Fitness
Glucose
/ metabolism
Microbial Sensitivity Tests
Mutation
Nucleotidyltransferases
/ genetics
Oxidation-Reduction
Transferases (Other Substituted Phosphate Groups)
/ genetics
Viridans Streptococci
/ drug effects
Antibiotic resistance
Daptomycin
Metabolism
Streptococcus
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
15 06 2020
15 06 2020
Historique:
received:
14
01
2020
accepted:
09
06
2020
entrez:
17
6
2020
pubmed:
17
6
2020
medline:
27
5
2021
Statut:
epublish
Résumé
Viridans group streptococci of the Streptococcus mitis-oralis subgroup are important endovascular pathogens. They can rapidly develop high-level and durable non-susceptibility to daptomycin both in vitro and in vivo upon exposure to daptomycin. Two consistent genetic adaptations associated with this phenotype (i.e., mutations in cdsA and pgsA) lead to the depletion of the phospholipids, phosphatidylglycerol and cardiolipin, from the bacterial membrane. Such alterations in phospholipid biosynthesis will modify carbon flow and change the bacterial metabolic status. To determine the metabolic differences between daptomycin-susceptible and non-susceptible bacteria, the physiology and metabolomes of S. mitis-oralis strains 351 (daptomycin-susceptible) and 351-D10 (daptomycin non-susceptible) were analyzed. S. mitis-oralis strain 351-D10 was made daptomycin non-susceptible through serial passage in the presence of daptomycin. Daptomycin non-susceptible S. mitis-oralis had significant alterations in glucose catabolism and a re-balancing of the redox status through amino acid biosynthesis relative to daptomycin susceptible S. mitis-oralis. These changes were accompanied by a reduced capacity to generate biomass, creating a fitness cost in exchange for daptomycin non-susceptibility. S. mitis-oralis metabolism is altered in daptomycin non-susceptible bacteria relative to the daptomycin susceptible parent strain. As demonstrated in Staphylococcus aureus, inhibiting the metabolic changes that facilitate the transition from a daptomycin susceptible state to a non-susceptible one, inhibits daptomycin non-susceptibility. By preventing these metabolic adaptations in S. mitis-oralis, it should be possible to deter the formation of daptomycin non-susceptibility.
Sections du résumé
BACKGROUND
Viridans group streptococci of the Streptococcus mitis-oralis subgroup are important endovascular pathogens. They can rapidly develop high-level and durable non-susceptibility to daptomycin both in vitro and in vivo upon exposure to daptomycin. Two consistent genetic adaptations associated with this phenotype (i.e., mutations in cdsA and pgsA) lead to the depletion of the phospholipids, phosphatidylglycerol and cardiolipin, from the bacterial membrane. Such alterations in phospholipid biosynthesis will modify carbon flow and change the bacterial metabolic status. To determine the metabolic differences between daptomycin-susceptible and non-susceptible bacteria, the physiology and metabolomes of S. mitis-oralis strains 351 (daptomycin-susceptible) and 351-D10 (daptomycin non-susceptible) were analyzed. S. mitis-oralis strain 351-D10 was made daptomycin non-susceptible through serial passage in the presence of daptomycin.
RESULTS
Daptomycin non-susceptible S. mitis-oralis had significant alterations in glucose catabolism and a re-balancing of the redox status through amino acid biosynthesis relative to daptomycin susceptible S. mitis-oralis. These changes were accompanied by a reduced capacity to generate biomass, creating a fitness cost in exchange for daptomycin non-susceptibility.
CONCLUSIONS
S. mitis-oralis metabolism is altered in daptomycin non-susceptible bacteria relative to the daptomycin susceptible parent strain. As demonstrated in Staphylococcus aureus, inhibiting the metabolic changes that facilitate the transition from a daptomycin susceptible state to a non-susceptible one, inhibits daptomycin non-susceptibility. By preventing these metabolic adaptations in S. mitis-oralis, it should be possible to deter the formation of daptomycin non-susceptibility.
Identifiants
pubmed: 32539684
doi: 10.1186/s12866-020-01849-w
pii: 10.1186/s12866-020-01849-w
pmc: PMC7296729
doi:
Substances chimiques
Amino Acids
0
Bacterial Proteins
0
Nucleotidyltransferases
EC 2.7.7.-
phosphatidate cytidylyltransferase
EC 2.7.7.41
Transferases (Other Substituted Phosphate Groups)
EC 2.7.8.-
CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase
EC 2.7.8.5
Glucose
IY9XDZ35W2
Daptomycin
NWQ5N31VKK
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
162Subventions
Organisme : NIAID NIH HHS
ID : R01 AI130056
Pays : United States
Organisme : NIGMS NIH HHS
ID : GM113126
Pays : United States
Organisme : NIGMS NIH HHS
ID : GM103335
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : AI130056
Pays : International
Références
Metabolomics. 2018 Aug 10;14(8):108
pubmed: 30830388
Antimicrob Agents Chemother. 2007 Sep;51(9):3445-8
pubmed: 17620372
Anal Chem. 2008 May 15;80(10):3783-90
pubmed: 18419139
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29109158
ACS Chem Biol. 2014 May 16;9(5):1138-44
pubmed: 24576144
J Biomol NMR. 1995 Nov;6(3):277-93
pubmed: 8520220
Antimicrob Agents Chemother. 2008 Jan;52(1):269-78
pubmed: 17954690
J Antimicrob Chemother. 2019 Aug 1;74(8):2274-2283
pubmed: 31074482
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30509945
Antimicrob Agents Chemother. 2009 Jun;53(6):2312-8
pubmed: 19332678
Clin Microbiol Infect. 2019 Apr;25(4):518-520
pubmed: 30528371
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28223392
Antimicrob Agents Chemother. 2013 May;57(5):2319-25
pubmed: 23478959
Antimicrob Agents Chemother. 2006 Jun;50(6):2137-45
pubmed: 16723576
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28193649
Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
Antimicrob Agents Chemother. 2015 Jul;59(7):4226-38
pubmed: 25963986
Microbiol Spectr. 2015 Jun;3(3):
pubmed: 26185086
Microbiol Mol Biol Rev. 2009 Jun;73(2):233-48
pubmed: 19487727
Metabolites. 2019 Mar 22;9(3):
pubmed: 30909447
J Med Microbiol. 2008 Aug;57(Pt 8):1036-1038
pubmed: 18628509
J Magn Reson. 2005 Aug;175(2):340-6
pubmed: 15964227
Methods Mol Biol. 2004;278:313-52
pubmed: 15318002
Antimicrob Agents Chemother. 2011 May;55(5):2018-25
pubmed: 21343446
Arch Intern Med. 2002 Jan 14;162(1):90-4
pubmed: 11784225
Arch Intern Med. 2009 Mar 9;169(5):463-73
pubmed: 19273776
Nucleic Acids Res. 2005 Oct 24;33(19):6083-9
pubmed: 16246909
Infect Immun. 1983 Jun;40(3):1146-54
pubmed: 6343241
Antimicrob Agents Chemother. 2019 Jul 25;63(8):
pubmed: 31182540
Nucleic Acids Res. 2013 Jan;41(Database issue):D801-7
pubmed: 23161693
Cancer. 2006 Apr 15;106(8):1815-20
pubmed: 16534785
J Magn Reson. 2010 Feb;202(2):190-202
pubmed: 20004603
J Magn Reson. 2015 Dec;261:19-26
pubmed: 26524650
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28115347